December 10, 2015
Wellesley, Mass., December 10, 2015 – The global erythropoietin biosimilars drug market has been growing rapidly in the past decade, primarily due to the patent expiry of major erythropoietin biologic drug in European market and demand for cheaper priced erythropoietin drugs in the Asia-Pacific, South America, Middle-East and African markets. BCC Research projects in its new report that during next five years the global market for erythropoietin biosimilars will see healthy gains while the global market for erythropoietin biologics will shrink substantially.
Erythropoietin is a glycoprotein hormone that stimulates the stem cells of the bone marrow for the production of red blood cells. Its other therapeutic functions include initiating the synthesis of hemoglobin and stimulating wound healing, as well as playing a vital role in the brain’s response to neuronal injury. Erythropoietin, which is made naturally in the human body (biologic), also can be made synthetically (biosimilar).
The global erythropoietin drug market is expected to reach nearly $7.2 billion and nearly $7.3 billion in 2015 and 2020, respectively, reflecting a five-year compound annual growth rate (CAGR) of 0.2%.
By drug category, the erythropoietin biologics drug market is projected to account for 90% and 72.9% in 2015 and 2020, respectively, of the total market. The erythropoietin biosimilars drug market is projected to account for 9.6% and 27.1% in 2015 and 2020, respectively, of the total market.
More specifically, the erythropoietin biologics drug market should reach $6.5 billion in 2015, reflecting a year-on-year (YOY) growth rate of 4.8%. However, the market is expected to decline at a five-year (2015-2020) CAGR of -4.1% to reach $5.3 billion in the end year. The decline stems chiefly from the patent expiry of Epogen in the U.S. in 2015, and of Aranesp in Europe in 2016.
The erythropoietin biosimilars drug market is expected to reach $696.2 million in 2015, reflecting a YOY growth rate of 17.5%. The market is expected to grow at a five-year CAGR of 23.2% to reach $2 billion in 2020. The anticipated entry of biosimilars in the U.S. market and increasing demand for erythropoietin biosimilars, particularly in developing countries such as India and China, will drive this growth.
The demand for erythropoietin biosimilars drugs is expected to increase in the U.S. and the Europe market, as well.
“The entrant of erythropoietin biosimilars in Europe and the U.S. will create a huge impact during the forecast period, resulting in a decline in the global erythropoietin drug market,” says BCC Research analyst Aneesh Kumar. “This decline is due to both the expiry of major patented drugs and the entrant of many biosimilar erythropoietin drug in the European market, which are approximately 20% to 30% cheaper compared to patented drugs.”
Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets (PHM130A) examines the market in value terms broken down by major types of erythropoietin, by major regions, and by applications. The report identifies growth drivers and opportunities, and provides revenues projections through 2020.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets( PHM130A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.